Difficult to control atopic dermatitis

Ulf Darsow, Andreas Wollenberg, Dagmar Simon, Alain Taïeb, Thomas Werfel, Arnold Oranje, Carlo Gelmetti, Ake Svensson, Mette Deleuran, Anne Marie Calza, Francesca Giusti, Jann Lübbe, Stefania Seidenari, Johannes Ring

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. "Eczema school" educational programs have been proven to be helpful.

Original languageEnglish
Article number6
JournalWorld Allergy Organization Journal
Volume6
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Atopic Dermatitis
Eczema
Anti-Inflammatory Agents
Superinfection
Local Anti-Infective Agents
Histamine Antagonists
Tacrolimus
Therapeutics
Pruritus
Disease Progression
Adrenal Cortex Hormones
Calcineurin Inhibitors

Keywords

  • Atopic dermatitis
  • Eczema
  • Guideline
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Darsow, U., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A., ... Ring, J. (2013). Difficult to control atopic dermatitis. World Allergy Organization Journal, 6(1), [6]. https://doi.org/10.1186/1939-4551-6-6

Difficult to control atopic dermatitis. / Darsow, Ulf; Wollenberg, Andreas; Simon, Dagmar; Taïeb, Alain; Werfel, Thomas; Oranje, Arnold; Gelmetti, Carlo; Svensson, Ake; Deleuran, Mette; Calza, Anne Marie; Giusti, Francesca; Lübbe, Jann; Seidenari, Stefania; Ring, Johannes.

In: World Allergy Organization Journal, Vol. 6, No. 1, 6, 2013.

Research output: Contribution to journalArticle

Darsow, U, Wollenberg, A, Simon, D, Taïeb, A, Werfel, T, Oranje, A, Gelmetti, C, Svensson, A, Deleuran, M, Calza, AM, Giusti, F, Lübbe, J, Seidenari, S & Ring, J 2013, 'Difficult to control atopic dermatitis', World Allergy Organization Journal, vol. 6, no. 1, 6. https://doi.org/10.1186/1939-4551-6-6
Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A et al. Difficult to control atopic dermatitis. World Allergy Organization Journal. 2013;6(1). 6. https://doi.org/10.1186/1939-4551-6-6
Darsow, Ulf ; Wollenberg, Andreas ; Simon, Dagmar ; Taïeb, Alain ; Werfel, Thomas ; Oranje, Arnold ; Gelmetti, Carlo ; Svensson, Ake ; Deleuran, Mette ; Calza, Anne Marie ; Giusti, Francesca ; Lübbe, Jann ; Seidenari, Stefania ; Ring, Johannes. / Difficult to control atopic dermatitis. In: World Allergy Organization Journal. 2013 ; Vol. 6, No. 1.
@article{a823574cf9b24cfabf6a98cd4432b471,
title = "Difficult to control atopic dermatitis",
abstract = "Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. {"}Eczema school{"} educational programs have been proven to be helpful.",
keywords = "Atopic dermatitis, Eczema, Guideline, Therapy",
author = "Ulf Darsow and Andreas Wollenberg and Dagmar Simon and Alain Ta{\"i}eb and Thomas Werfel and Arnold Oranje and Carlo Gelmetti and Ake Svensson and Mette Deleuran and Calza, {Anne Marie} and Francesca Giusti and Jann L{\"u}bbe and Stefania Seidenari and Johannes Ring",
year = "2013",
doi = "10.1186/1939-4551-6-6",
language = "English",
volume = "6",
journal = "World Allergy Organization Journal",
issn = "1939-4551",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Difficult to control atopic dermatitis

AU - Darsow, Ulf

AU - Wollenberg, Andreas

AU - Simon, Dagmar

AU - Taïeb, Alain

AU - Werfel, Thomas

AU - Oranje, Arnold

AU - Gelmetti, Carlo

AU - Svensson, Ake

AU - Deleuran, Mette

AU - Calza, Anne Marie

AU - Giusti, Francesca

AU - Lübbe, Jann

AU - Seidenari, Stefania

AU - Ring, Johannes

PY - 2013

Y1 - 2013

N2 - Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. "Eczema school" educational programs have been proven to be helpful.

AB - Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. "Eczema school" educational programs have been proven to be helpful.

KW - Atopic dermatitis

KW - Eczema

KW - Guideline

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84887835818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887835818&partnerID=8YFLogxK

U2 - 10.1186/1939-4551-6-6

DO - 10.1186/1939-4551-6-6

M3 - Article

C2 - 23663504

AN - SCOPUS:84887835818

VL - 6

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

SN - 1939-4551

IS - 1

M1 - 6

ER -